2 drug(s) with this reaction
8,497 total reports
Osteonecrosis Of Jaw has been reported as an adverse reaction across 2 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 8,497 adverse event reports mention osteonecrosis of jaw in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with osteonecrosis of jaw, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have osteonecrosis of jaw listed in their FDA adverse event reports, sorted by report count:
In addition to osteonecrosis of jaw, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
2 drug(s) manufactured by Amgen Inc have osteonecrosis of jaw listed in their FDA adverse event reports: DENOSUMAB, ROMOSOZUMAB-AQQG.
There are a combined 8,497 reports of osteonecrosis of jaw across 2 Amgen Inc drug(s) in the FDA adverse event database.